Regeneron: Drug Pricing Woes Notwithstanding, Due For A Major Comeback

Group 1 - The article discusses the performance of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), highlighting an 8% increase in revenues to $14.2 billion and a GAAP net income per diluted share of $38.34 for 2024 [1] - The investing group Haggerston BioHealth provides insights into the biotech, pharma, and healthcare sectors, offering forecasts, financial statements, and market analyses [1] - Edmund Ingham, a biotech consultant with over 5 years of experience, leads the Haggerston BioHealth investing group and has compiled detailed reports on more than 1,000 companies [1]